KNSA Q4 2023 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$83M+34.8% YoY

Gross Profit

$57M67.9% margin

Operating Income

$81,0000.1% margin

Net Income

$25M30.3% margin

EPS (Diluted)

$0.35

QoQ Revenue Growth

+24.4%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$4M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$526M

Total Liabilities

$87M

Stockholders' Equity

$439M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$83M	$62M	+34.8%
Gross Profit	$57M	$48M	+18.9%
Operating Income	$81,000	$6M	-98.7%
Net Income	$25M	$4M	+465.7%

Revenue Segments

Product

$136M90%

Collaboration

$14M10%